F-star, an invoX Company

A clinical-stage biopharma company developing next generation bispecific antibodies to transform the lives of patients with cancer and other serious diseases.

[F-star, an invoX Company @Fstar_Inc]

Check out our redesigned logo and website. The new logo conveys a feeling of forward movement and the promise of our tetravalent #bispecific approach with an elongated 4-part graphic that goes from blue to orange representing tumors going from cold to hot with our treatments.

[F-star, an invoX Company @Fstar_Inc]

F-star enters strategic discovery collaboration and licence agreement with Takeda to leverage F-star’s proprietary fully-human Fcab™ and tetravalent mAb² ™ platforms to R&D next-gen multi-specific immunotherapies for cancer
https://t.co/fErFgmFNZS

[F-star, an invoX Company @Fstar_Inc]

We announced a license agreement with Takeda for 2nd novel next-gen immuno-oncology bispecific antibody.

The bispecific antibody is directed towards an undisclosed Takeda immuno-oncology target using F-star’s proprietary Fcab™ and mAb2™ platforms.
https://t.co/ybaDm9DGgb

[F-star, an invoX Company @Fstar_Inc]

invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.

https://t.co/5TqDy0t7Ku.

[F-star, an invoX Company @Fstar_Inc]

F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma

Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender Offer
https://t.co/ySKTk34MOp

[F-star, an invoX Company @Fstar_Inc]

Data published on safety and efficacy results from Phase 1 trial of FS118 in patients with advanced #cancer and PD-L1 resistance demonstrate that FS118 has the potential to overcome cancer immune resistance given the prolonged pharmacodynamic activity
https://t.co/ewYT4nAqlu

[F-star, an invoX Company @Fstar_Inc]

Check out the case study led by Dr. Deborah Wong at UCLA of FS118, our bispecific LAG3/PD-L1 antagonist. To learn more about FS118, visit our website: https://t.co/r35S8oVq32

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC case report: Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report https://t.co/xZn6ALSJh0

[F-star, an invoX Company @Fstar_Inc]

We are profoundly saddened at the news of the death of Her Majesty Queen Elizabeth and are deeply grateful for her seven decades of unparalleled service to the nation. F-star would like to extend our sincere condolences to the entire Royal Family.

[F-star, an invoX Company @Fstar_Inc]

We are delighted to announce a new partnership w/@TakedaPharma for a novel #immunooncology #bispecific antibody based on F-star’s proprietary Fcab™ and mAb2™ platforms.
https://t.co/GbzmdzFuOi

[F-star, an invoX Company @Fstar_Inc]

Wishing our US colleagues, partners, collaborators and patients a happy, fun and safe Fourth of July holiday and weekend.

[F-star, an invoX Company @Fstar_Inc]

We are excited to announce the proposed acquisition of F-star Therapeutics. Inc. by invoX. This enables greater opportunities to develop the F-star platform as we work together towards a future free from cancer and other serious diseases. details here: https://t.co/0e9hEsFYKE

[F-star, an invoX Company @Fstar_Inc]

ICYMI: We were thrilled to be on @businessweekly #Killer50 list. Read about it here: https://t.co/e6QBvamyhM

[F-star, an invoX Company @Fstar_Inc]

As part of this collaboration Institut Bergonié is assessing TLS presence in pts treated w/ F-star therapeutic. We will continue to investigate the value of TLS as potential biomarker for our assets as 1 strategy to drive patient selection & response. https://t.co/a6lwj6K69Z

[F-star, an invoX Company @Fstar_Inc]

We are excited to see the publication in Nature Medicine by Antoine Italiano et al which suggests that tertiary lymphoid structures (TLS) presence in advanced soft tissue sarcoma is a potential predictive biomarker for CPI treatment.

[F-star, an invoX Company @Fstar_Inc]

We believe TLS provide the ideal environment from which F-star’s next generation #bispecifics can drive an anti-tumor response. F-star is pleased to announce that we are collaborating with Dr. Antoine Italiano at Institut Bergonié in Bordeaux.

[F-star, an invoX Company @Fstar_Inc]

Watch “Our Technology in Action” on #Vimeo https://t.co/1BYRgEJa0s to learn about the 3 "Cs" of how our novel tetravalent bispecifics active the immune system with Crosslinking, Clustering and Conditionality.
#Immunooncology #CancerResearchUK

[F-star, an invoX Company @Fstar_Inc]

We announced Q1 results & business update. @EliotForster will host a webcast at 9 a.m. ET today
Some highlights:
Patients dosed in EU, expanding FS120 and FS118 studies beyond the US
4 Clinical readouts anticipated in 2022
https://t.co/reUTd7RXoP

[F-star, an invoX Company @Fstar_Inc]

We're at #AACR2022 presenting data on FS118 our first-in-class LAG-3/PD-L1 bispecific antibody, demonstrating its novel LAG-3 shedding mechanism.
https://t.co/iNEwqKlnXu

[F-star, an invoX Company @Fstar_Inc]

We are pleased to be included in the "Future of Cancer Immunotherapy" issue of @cenmag. Our CMO, Dr. Louis Kayitalire discusses the opportunities in immuno-oncology of our novel tetravalent #bispecific platform. https://t.co/qxi59AzriV

[F-star, an invoX Company @Fstar_Inc]

We look forward to attending #AACR2022 and presenting on our tetravalent bispecific antibody, FS118 targeting LAG-3 and PD-L1. https://t.co/r35S8oUSdu
#immunooncology #cancerresearch

[F-star, an invoX Company @Fstar_Inc]

Great event today with @BSI_TumourImm We presented posters on two of our tetravalent #bispecific antibodies, FS120 and FS222. #checkpointblockade2022
https://t.co/uEwjoxAcmx
#immunooncology